EGFR and non-small cell lung carcinoma: The drugs for the treatment of NSCLC caused by EGFR mutations, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), have gone through three generations of targeted drugs and are expected to usher in a fourth generation of targeted drugs (31) (Table 1).